Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference90 articles.
1. Offidani M, Corvatta L, More S, Nappi D, Martinelli G, Olivieri A, et al. Daratumumab for the management of newly diagnosed and relapsed/refractory multiple myeloma: current and emerging treatments. Front Oncol. 2020;10:624661. https://doi.org/10.3389/fonc.2020.624661.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.
3. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–8. https://doi.org/10.1038/leu.2017.138.
4. US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. FDA letter for BLA 761036. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/761036Orig1s000ltr.pdf. Accessed 13 Oct 2022.
5. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https://doi.org/10.1056/NEJMoa1607751.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献